These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 4997395

  • 1. Asparaginase: molecular and enzymic requirements for use as an antileukaemia agent.
    Wade HE.
    J Gen Microbiol; 1971 Mar; 65(3):x-xi. PubMed ID: 4997395
    [No Abstract] [Full Text] [Related]

  • 2. Erwinia carotovora asparaginase in patients with prior anaphylaxis to asparaginase from E. coli.
    Ohnuma T, Holland JF, Meyer P.
    Cancer; 1972 Aug; 30(2):376-81. PubMed ID: 4559405
    [No Abstract] [Full Text] [Related]

  • 3. A comparative study of the antitumor effectiveness of E. coli and Erwinia asparaginases.
    Roberts J, Schmid FA, Old LJ, Stockert E.
    Cancer Biochem Biophys; 1976 May; 1(4):175-8. PubMed ID: 788892
    [Abstract] [Full Text] [Related]

  • 4. Therapy with Erwinia L-asparaginase in children with acute leukemia after anaphylaxis to E. coli L-asparaginase.
    King OY, Wilbur JR, Mumford DM, Sutow WW.
    Cancer; 1974 Mar; 33(3):611-4. PubMed ID: 4592901
    [No Abstract] [Full Text] [Related]

  • 5. Asparaginase and amino acids in cancer therapeutics. Cancer and Leukemia Group B Investigators.
    Holland JF, Ohnuma T.
    Cancer Treat Rep; 1981 Mar; 65 Suppl 4():123-30. PubMed ID: 7049376
    [Abstract] [Full Text] [Related]

  • 6. Clinical experience with L-asparaginase.
    Hamilton-Fairley G, Malpas JS, Galton DA.
    Recent Results Cancer Res; 1970 Mar; 33():257-62. PubMed ID: 4949164
    [No Abstract] [Full Text] [Related]

  • 7. The effects of immunization to L-asparaginase on antitumor and enzymatic activity.
    Goldberg AI, Cooney DA, Glynn JP, Homan ER, Gaston MR, Milman HA.
    Cancer Res; 1973 Feb; 33(2):256-61. PubMed ID: 4569788
    [No Abstract] [Full Text] [Related]

  • 8. [Asparaginase].
    Boiron M, Jacquillat C, Weil M, Tanzer J, Bernard J.
    Presse Med (1893); 1968 Nov 16; 76(44):2099-101. PubMed ID: 4882819
    [No Abstract] [Full Text] [Related]

  • 9. [Preliminary studies on the treatment of acute lymphocytic leukemia of the child with L-asparaginase].
    Astaldi G, Burgio GR, Severi F, Genova R, Curtoni E, Bruschelli M, Astaldi AA.
    Haematol Lat; 1968 Nov 16; 11(4):311-47. PubMed ID: 4899936
    [No Abstract] [Full Text] [Related]

  • 10. Comparison of anaphylactic reactions to asparaginase derived from Escherichia coli and from Erwinia cultures.
    Dellinger CT, Miale TD.
    Cancer; 1976 Oct 16; 38(4):1843-6. PubMed ID: 791476
    [Abstract] [Full Text] [Related]

  • 11. The "other" asparaginase.
    Hrushesky WJ, Slavik M, Penta J, Muggia F.
    Med Pediatr Oncol; 1976 Oct 16; 2(4):441-2. PubMed ID: 794672
    [No Abstract] [Full Text] [Related]

  • 12. L-asparaginase--antileukemia agent.
    Bukhari SZ, Yaqub M.
    J Pak Med Assoc; 1977 Jan 16; 27(1):262-4. PubMed ID: 19639
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics and drug monitoring of L-asparaginase treatment.
    Boos J.
    Int J Clin Pharmacol Ther; 1997 Mar 16; 35(3):96-8. PubMed ID: 9088996
    [Abstract] [Full Text] [Related]

  • 14. [Immobilized asparaginase and its use in medicine].
    Kozlov EA, Petriĭ OP.
    Vopr Med Khim; 1978 Mar 16; 24(6):723-33. PubMed ID: 32657
    [No Abstract] [Full Text] [Related]

  • 15. L-asparaginase activity in plasma and other biological fluids.
    Schwartz MK, Lash ED, Oettgen HF, Tomato FA.
    Cancer; 1970 Feb 16; 25(2):244-52. PubMed ID: 4905152
    [No Abstract] [Full Text] [Related]

  • 16. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
    Kwok CS, Kham SK, Ariffin H, Lin HP, Quah TC, Yeoh AE.
    Pediatr Blood Cancer; 2006 Sep 16; 47(3):299-304. PubMed ID: 16302217
    [Abstract] [Full Text] [Related]

  • 17. Characterization of polyethylene glycol-modified L-asparaginase from Escherichia coli and its application to therapy of leukemia.
    Yoshimoto T, Nishimura H, Saito Y, Sakurai K, Kamisaki Y, Wada H, Sako M, Tsujino G, Inada Y.
    Jpn J Cancer Res; 1986 Dec 16; 77(12):1264-70. PubMed ID: 3102431
    [Abstract] [Full Text] [Related]

  • 18. [Relationship between the magnitude of Km and pH for L-asparaginase].
    Libinson GS, Mikhalev AV.
    Biokhimiia; 1976 Jan 16; 41(1):149-52. PubMed ID: 6070
    [Abstract] [Full Text] [Related]

  • 19. [Increase of immunoglobulins and formation of antibodies in the course of asparaginase treatment].
    Lamerz R, Fateh-Moghadam A, Hornung B, Ehrhart H.
    Klin Wochenschr; 1971 Mar 15; 49(6):360-4. PubMed ID: 4932029
    [No Abstract] [Full Text] [Related]

  • 20. L-asparaginase and human malignant disease.
    Crowther D.
    Nature; 1971 Jan 15; 229(5281):168-71. PubMed ID: 4923259
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.